A Study to Determine the Safety and Tolerability of Dupilumab (REGN668/SAR231893) in Patients Aged ≥6 to <18 Years With Atopic Dermatitis (Eczema)
Clinical trial NCT02407756 · COMPLETED
Trial details
- NCT number
- NCT02407756
- Sponsor
- Regeneron Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2015-03-31
- Primary completion
- 2016-03-31
- Enrollment
- 78
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.